Literature DB >> 2046673

Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells.

M D Sklar1, E Thompson, M J Welsh, M Liebert, J Harney, H B Grossman, M Smith, E V Prochownik.   

Abstract

ras oncogene-transformed NIH 3T3 cells expressing glucocorticoid-inducible antisense c-myc cDNA transcripts at levels sufficient to deplete c-myc protein lost their transformed morphology and the ability to grow in soft agar; their ability to form tumors in nude mice was also impaired. These changes were dependent on the continuous expression of the antisense sequences. No major effects on plating efficiencies, growth rates in monolayer culture, or immortalization were observed in the revertant cells, indicating that the observed effects were not a toxic consequence of c-myc protein depletion. Transfection with the same vector expressing c-myc in the sense orientation or other control vectors had no effect on transformation. These results suggest that a certain minimum level of expression of c-myc is required for the maintenance of ras transformation in NIH 3T3 cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2046673      PMCID: PMC361133          DOI: 10.1128/mcb.11.7.3699-3710.1991

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  56 in total

1.  The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice.

Authors:  W Y Langdon; A W Harris; S Cory; J M Adams
Journal:  Cell       Date:  1986-10-10       Impact factor: 41.582

2.  Microinjection of transforming ras protein induces c-fos expression.

Authors:  D W Stacey; T Watson; H F Kung; T Curran
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

3.  Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts.

Authors:  H Land; A C Chen; J P Morgenstern; L F Parada; R A Weinberg
Journal:  Mol Cell Biol       Date:  1986-06       Impact factor: 4.272

4.  Malignant transformation of early passage rodent cells by a single mutated human oncogene.

Authors:  D A Spandidos; N M Wilkie
Journal:  Nature       Date:  1984 Aug 9-15       Impact factor: 49.962

5.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.

Authors:  H Land; L F Parada; R A Weinberg
Journal:  Nature       Date:  1983 Aug 18-24       Impact factor: 49.962

6.  Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor.

Authors:  K Kelly; B H Cochran; C D Stiles; P Leder
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

7.  Cell-cycle control of c-myc but not c-ras expression is lost following chemical transformation.

Authors:  J Campisi; H E Gray; A B Pardee; M Dean; G E Sonenshein
Journal:  Cell       Date:  1984-02       Impact factor: 41.582

8.  Differential responsiveness of myc- and ras-transfected cells to growth factors: selective stimulation of myc-transfected cells by epidermal growth factor.

Authors:  D F Stern; A B Roberts; N S Roche; M B Sporn; R A Weinberg
Journal:  Mol Cell Biol       Date:  1986-03       Impact factor: 4.272

9.  Nucleotide sequence comparison of normal and translocated murine c-myc genes.

Authors:  L W Stanton; P D Fahrlander; P M Tesser; K B Marcu
Journal:  Nature       Date:  1984 Aug 2-8       Impact factor: 49.962

10.  c-fos protein can induce cellular transformation: a novel mechanism of activation of a cellular oncogene.

Authors:  A D Miller; T Curran; I M Verma
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

View more
  14 in total

1.  Regulation of collagen I gene expression by ras.

Authors:  J L Slack; M I Parker; V R Robinson; P Bornstein
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

2.  CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling.

Authors:  Songyun Zhu; Kyungsil Yoon; Esta Sterneck; Peter F Johnson; Robert C Smart
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

3.  Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src.

Authors:  N Aziz; H Cherwinski; M McMahon
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

Review 4.  Antisense oncogene and tumor suppressor gene therapy of cancer.

Authors:  W W Zhang
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

5.  Regulation of the junB gene by v-src.

Authors:  I Apel; C L Yu; T Wang; C Dobry; M E Van Antwerp; R Jove; E V Prochownik
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

6.  Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis.

Authors:  B Rudolph; R Saffrich; J Zwicker; B Henglein; R Müller; W Ansorge; M Eilers
Journal:  EMBO J       Date:  1996-06-17       Impact factor: 11.598

7.  An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc.

Authors:  R M Jones; J Branda; K A Johnston; M Polymenis; M Gadd; A Rustgi; L Callanan; E V Schmidt
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

8.  Cell cycle-dependent phosphorylation of C/EBPbeta mediates oncogenic cooperativity between C/EBPbeta and H-RasV12.

Authors:  Jon D Shuman; Thomas Sebastian; Philipp Kaldis; Terry D Copeland; Songyun Zhu; Robert C Smart; Peter F Johnson
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

Review 9.  Gene therapy in surgical oncology.

Authors:  S P Gagandeep; G J Poston; A R Kinsella
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

10.  Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein.

Authors:  S J Leevers; C J Marshall
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.